Segui
Dirk Schadendorf
Dirk Schadendorf
Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen
Email verificata su uk-essen.de
Titolo
Citata da
Citata da
Anno
Improved survival with ipilimumab in patients with metastatic melanoma
FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ...
New England Journal of Medicine 363 (8), 711-723, 2010
169372010
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
90232011
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
78132015
Nivolumab in previously untreated melanoma without BRAF mutation
C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ...
New England journal of medicine 372 (4), 320-330, 2015
59752015
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
42872018
Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells
FO Nestle, S Alijagic, M Gilliet, Y Sun, S Grabbe, R Dummer, G Burg, ...
Nature medicine 4 (3), 328-332, 1998
38771998
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
34922017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
29542019
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
29282016
A landscape of driver mutations in melanoma
E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ...
Cell 150 (2), 251-263, 2012
29022012
Improved overall survival in melanoma with combined dabrafenib and trametinib
C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ...
New England Journal of Medicine 372 (1), 30-39, 2015
28662015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
26752015
Genomic classification of cutaneous melanoma
R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ...
Cell 161 (7), 1681-1696, 2015
26302015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
25622012
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
24942018
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
D Schadendorf, FS Hodi, C Robert, JS Weber, K Margolin, O Hamid, ...
Journal of clinical oncology 33 (17), 1889, 2015
23792015
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
23772018
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
21052018
TERT promoter mutations in familial and sporadic melanoma
S Horn, A Figl, PS Rachakonda, C Fischer, A Sucker, A Gast, S Kadel, ...
Science 339 (6122), 959-961, 2013
20372013
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
19762018
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20